ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,03
-0,69%
Dow Jones
40 829,12
1,54%
DAX
18 518,03
-0,44%
Brent Oil
83,345
-1,18%
Bitcoin
64 309,46
-0,84%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Royaume-Uni
  5. LSE
  6. Hutchison China Meditech Ltd (0J7G)

  7. Hutchison China Meditech Ltd (0J7G) Actualités

0J7G

Hutchison China Meditech (0J7G)

Hutchison China Meditech Ltd
De:
Trier par:
 Showing the most relevant articles for your search:LSE:0J7G
DateHeureSourceTitreSymboleSociété
28/02/202309h30UK RegulatoryHutchmed (China) Limited 2022 Full Year Results and Business UpdatesLSE:0J7GHutchison China Meditech Ltd
27/02/202311h00RNS Non-RegulatoryHutchmed (China) Limited Enrollment Completed in Phase 2 Amdizalisib trialLSE:0J7GHutchison China Meditech Ltd
31/01/202309h30UK RegulatoryHutchmed (China) Limited Notice of ResultsLSE:0J7GHutchison China Meditech Ltd
23/01/202309h00UK RegulatoryHutchmed (China) Limited License to Takeda for Fruquintinib outside ChinaLSE:0J7GHutchison China Meditech Ltd
18/01/202315h30UK RegulatoryHutchmed (China) Limited Inclusion of ORPATHYS in NRDL in ChinaLSE:0J7GHutchison China Meditech Ltd
03/01/202309h30RNS Non-RegulatoryHutchmed (China) Limited Enrollment Completed in Phase 3 TrialLSE:0J7GHutchison China Meditech Ltd
30/12/202209h30UK RegulatoryHutchmed (China) Limited Blocklisting Six Monthly ReturnLSE:0J7GHutchison China Meditech Ltd
19/12/202211h00RNS Non-RegulatoryHutchmed (China) Limited FDA NDA Rolling Submission for FruquintinibLSE:0J7GHutchison China Meditech Ltd
15/11/202208h00UK RegulatoryHutchmed (China) Limited HUTCHMED Announces Strategy UpdateLSE:0J7GHutchison China Meditech Ltd
14/11/202208h00UK RegulatoryHutchmed (China) Limited Positive Topline Phase 3 Result in FruquintinibLSE:0J7GHutchison China Meditech Ltd
27/10/202213h30RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Phase 2/3 Trial of FruquintinibLSE:0J7GHutchison China Meditech Ltd
21/10/202210h30UK RegulatoryHutchmed (China) Limited Vesting of awards under the LTIPLSE:0J7GHutchison China Meditech Ltd
10/10/202210h30RNS Non-RegulatoryHutchmed (China) Limited Phase II/III Trial of Sovleplenib for in ChinaLSE:0J7GHutchison China Meditech Ltd
30/09/202210h30UK RegulatoryHutchmed (China) Limited Total Voting RightsLSE:0J7GHutchison China Meditech Ltd
14/09/202212h00UK RegulatoryHutchmed (China) Limited Share Option Scheme and Long Term Incentive PlanLSE:0J7GHutchison China Meditech Ltd
08/09/202208h00UK RegulatoryHutchmed (China) Limited FRESCO-2 Colorectal Cancer MRCT Data HighlightsLSE:0J7GHutchison China Meditech Ltd
23/08/202211h00UK RegulatoryHutchmed (China) Limited Holding(s) in CompanyLSE:0J7GHutchison China Meditech Ltd
23/08/202210h30RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED To Present FRESCO-2 Data at ESMO 2022LSE:0J7GHutchison China Meditech Ltd
09/08/202210h30RNS Non-RegulatoryHutchmed (China) Limited First Participant in Phase I Trial of IMG-004LSE:0J7GHutchison China Meditech Ltd
08/08/202210h30RNS Non-RegulatoryHutchmed (China) Limited Preliminary results from SAVANNAH Phase 2 TrialLSE:0J7GHutchison China Meditech Ltd
08/08/202208h00UK RegulatoryHutchmed (China) Limited FRESCO-2 Study Has Met Primary EndpointLSE:0J7GHutchison China Meditech Ltd
01/08/202213h04UK RegulatoryHutchmed (China) Limited Interim Results and Business UpdatesLSE:0J7GHutchison China Meditech Ltd
01/08/202208h00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Bridging Study of TazemetostatLSE:0J7GHutchison China Meditech Ltd
15/07/202210h30RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Phase I Trial of HMPL-A83LSE:0J7GHutchison China Meditech Ltd
13/07/202208h00RNS Non-RegulatoryHutchmed (China) Limited Results of SAVANNAH Global Phase II Trial at WCLCLSE:0J7GHutchison China Meditech Ltd
06/07/202208h00RNS Non-RegulatoryHutchmed (China) Limited First Participants in Phase I Trial of IMG-007LSE:0J7GHutchison China Meditech Ltd
27/06/202210h30UK RegulatoryHutchmed (China) Limited HUTCHMED to Announce 2022 Half-Year ResultsLSE:0J7GHutchison China Meditech Ltd
01/06/202210h30RNS Non-RegulatoryHutchmed (China) Limited TAZVERIK(R) Approved in Hainan Pilot ZoneLSE:0J7GHutchison China Meditech Ltd
24/05/202212h00UK RegulatoryHutchmed (China) Limited LTIP and Share OptionsLSE:0J7GHutchison China Meditech Ltd
16/05/202213h00UK RegulatoryHutchmed (China) Limited Appointment of Non--Executive DirectorLSE:0J7GHutchison China Meditech Ltd
 Showing the most relevant articles for your search:LSE:0J7G

Dernières Valeurs Consultées

BIT
P1VD36
NLBNPIT1VD36 20991231 15...
BIT
UC1H0C
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés